Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Bristol-Myers Squibb Company (BMY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,837,392
  • Shares Outstanding, K 1,632,200
  • Annual Sales, $ 20,776 M
  • Annual Income, $ 1,007 M
  • 36-Month Beta 1.08
  • Price/Sales 4.13
  • Price/Cash Flow 15.02
  • Price/Book 6.27

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 0.84
  • Number of Estimates 6
  • High Estimate 0.85
  • Low Estimate 0.81
  • Prior Year 0.68
  • Growth Rate Est. (year over year) +23.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.94 +12.04%
on 10/25/18
59.28 -11.28%
on 10/17/18
-4.92 (-8.56%)
since 10/12/18
3-Month
46.94 +12.04%
on 10/25/18
63.69 -17.43%
on 10/09/18
-7.37 (-12.29%)
since 08/14/18
52-Week
46.94 +12.04%
on 10/25/18
70.05 -24.93%
on 02/16/18
-8.66 (-14.14%)
since 11/14/17

Most Recent Stories

More News
Bristol-Myers Squibb (BMY) Gains As Market Dips: What You Should Know

Bristol-Myers Squibb (BMY) closed the most recent trading day at $52.61, moving +0.04% from the previous trading session.

BMY : 52.59 (unch)
Merck Starts Rolling BLA Submission for Ebola Vaccine V920

Merck (MRK) begins the rolling submission of a BLA for its investigational Ebola vaccine candidate V920 to the FDA.

MRK : 74.09 (-0.70%)
LLY : 109.81 (-2.30%)
INO : 4.91 (+1.45%)
BMY : 52.59 (unch)
Shire's Filing Accepted by FDA for Gattex's Label Expansion

The FDA accepts Shire's (SHPG) sNDA and is expected to take action in March 2019.

LLY : 109.81 (-2.30%)
SHPG : 180.08 (-0.43%)
PFE : 42.91 (-1.40%)
BMY : 52.59 (unch)
Bayer (BAYRY) Beats on Q3 Earnings, Revenue Estimates

Bayer (BAYRY) surpasses earnings and sales estimates in the third quarter of 2018 and reiterates outlook for 2018.

BAYRY : 18.2500 (-2.48%)
MRK : 74.09 (-0.70%)
LLY : 109.81 (-2.30%)
BMY : 52.59 (unch)
Cronos (CRON) to Report Q3 Earnings: What's in the Offing?

Cronos' (CRON) third-quarter results are likely benefit from the company's collaboration initiatives to become one of the most promising cannabis company.

CRON : 8.12 (-2.29%)
TLRY : 102.34 (-8.26%)
GILD : 70.55 (-0.52%)
BMY : 52.59 (unch)
Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?

We expect investors to focus on Tilray's (TLRY) pipeline updates when it reports third-quarter results.

TLRY : 102.34 (-8.26%)
NVS : 87.33 (-1.11%)
GILD : 70.55 (-0.52%)
BMY : 52.59 (unch)
AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark

AVEO Pharmaceuticals' (AVEO) loss is narrower than estimated in the third quarter. Also, the company???s revenues beat estimates.

AVEO : 1.91 (+2.69%)
LLY : 109.81 (-2.30%)
BMY : 52.59 (unch)
ALXN : 116.11 (-2.03%)
Endo (ENDP) Stock Declines Despite Q3 Earnings & Revenue Beat

Endo (ENDP) tops revenues and earnings expectations in the third quarter and raises its annual view. However, the results from the cellulite treatment trial are disappointing.

ENDP : 12.91 (-4.51%)
MRK : 74.09 (-0.70%)
GILD : 70.55 (-0.52%)
BMY : 52.59 (unch)
Catalyst (CPRX) Reports Q3 Loss as Expected & Pipeline Update

Catalyst (CPRX) provides pipeline update and the FDA sets action date of Nov 28, 2018 for its lead pipeline candidate, Firdapse during the third quarter of 2018.

MRK : 74.09 (-0.70%)
LLY : 109.81 (-2.30%)
CPRX : 2.80 (-2.44%)
BMY : 52.59 (unch)
Keryx's (KERX) Loss Narrower Than Expected in Q3, Sales Lag

Keryx's (KERX) sole marketed product generates sales of $26.6 million in the third quarter, up 96% from the year-ago quarter.

KERX : 2.76 (-4.83%)
MRK : 74.09 (-0.70%)
LLY : 109.81 (-2.30%)
BMY : 52.59 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade BMY with:

Business Summary

Bristol-Myers Squibb is a differentiated company, led by their unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. They work every day to deliver innovative medicines for patients with serious...

See More

Key Turning Points

2nd Resistance Point 53.27
1st Resistance Point 52.93
Last Price 52.59
1st Support Level 52.26
2nd Support Level 51.94

See More

52-Week High 70.05
Fibonacci 61.8% 61.22
Fibonacci 50% 58.50
Fibonacci 38.2% 55.77
Last Price 52.59
52-Week Low 46.94

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar